These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease. Elmer LW; Juncos JL; Singer C; Truong DD; Criswell SR; Parashos S; Felt L; Johnson R; Patni R CNS Drugs; 2018 Apr; 32(4):387-398. PubMed ID: 29532440 [TBL] [Abstract][Full Text] [Related]
9. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. Rascol O; Tönges L; deVries T; Jaros M; Quartel A; Jacobs D; Parkinsonism Relat Disord; 2022 Mar; 96():65-73. PubMed ID: 35227940 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis. Pajo AT; Espiritu AI; Jamora RDG Neurodegener Dis Manag; 2019 Aug; 9(4):205-215. PubMed ID: 31392922 [No Abstract] [Full Text] [Related]
11. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients. Elkurd MT; Bahroo LB; Pahwa R Neurodegener Dis Manag; 2018 Apr; 8(2):73-80. PubMed ID: 29564954 [TBL] [Abstract][Full Text] [Related]
13. Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia. Mehta SH; Pahwa R; Tanner CM; Hauser RA; Johnson R Neurol Ther; 2021 Jun; 10(1):307-320. PubMed ID: 33864229 [TBL] [Abstract][Full Text] [Related]
14. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029 [TBL] [Abstract][Full Text] [Related]
15. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Wolf E; Seppi K; Katzenschlager R; Hochschorner G; Ransmayr G; Schwingenschuh P; Ott E; Kloiber I; Haubenberger D; Auff E; Poewe W Mov Disord; 2010 Jul; 25(10):1357-63. PubMed ID: 20198649 [TBL] [Abstract][Full Text] [Related]
16. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981 [TBL] [Abstract][Full Text] [Related]
17. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788 [TBL] [Abstract][Full Text] [Related]
18. Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Wolz M; Löhle M; Strecker K; Schwanebeck U; Schneider C; Reichmann H; Grählert X; Schwarz J; Storch A J Neural Transm (Vienna); 2010 Nov; 117(11):1279-86. PubMed ID: 20803300 [TBL] [Abstract][Full Text] [Related]